Indar, a private joint-stock company specializing in insulin production (Kyiv), saw its net profit drop by 23.6% in 2025 compared to 2024—to 12.388 million UAH.
According to the company’s disclosure in the National Securities and Stock Market Commission’s information disclosure system, revenue from sales in 2025 amounted to 562.024 million UAH, which is nearly 12% less than the previous year.
According to data from the OpenDataBot system, Indar’s revenue for the first quarter of 2026 was nearly 165 million UAH, with net profit of 4.844 million UAH.
Indar PJSC specializes in biotechnological drugs and is the only company in Ukraine with a full-cycle insulin production process: from the extraction of the active ingredient to the finished dosage form.
Indar’s core business is the production of insulin preparations, as well as medications for the blood coagulation system and metabolic therapy.
